Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 8 clinical trials
Cyclin D1 Based TPF(Docetaxel, Cisplatin and 5-fluorouracil) Induction Chemotherapy for OSCC(Oral Squamous Cell Carcinoma) Patients at cN2(Clinical Node 2) Stage: a Phase II Randomized Controlled Trial

The purpose of this study is to To confirm the predictive value of CCND1 for TPF induction in cN2 patients with OSCC

squamous cell carcinoma
mouth cancer
squamous cell carcinoma of the oral cavity
  • 20 Oct, 2022
  • 1 location
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6

This research study is studying a targeted therapy as a possible treatment for cancer abnormality in one of the following genes: CCND1, CCND2, CCND3, CDK4, or CDK6. The drug involved in

measurable disease
solid tumor
liver metastasis
solid neoplasm
neutrophil count
  • 24 Mar, 2022
  • 1 location
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, …

platelet count
direct bilirubin
lymphoid leukemia
monoclonal antibodies
  • 07 Oct, 2022
  • 3 locations
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial studies how well venetoclax and acalabrutinib work in treating patients with mantle cell lymphoma that did not respond to previous treatment or has come back. Venetoclax may cause cancer cell death by blocking the mechanism that cancer cells use to stay alive. Acalabrutinib may stop the …

platelet count
measurable disease
neutrophil count
  • 07 Oct, 2022
  • 1 location
A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects

This phase II trial studies how well olaparib works in treating patients with bladder cancer and other genitourinary tumors with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. PARPs are proteins that help …

follicle stimulating hormone
bladder cancer
measurable disease
  • 19 Oct, 2022
  • 2 locations
Immune Modulation by Abemaciclib in HNSCC. (AIM Trial)

This is a randomized, parallel, open label Phase II single-arm window trial to assess the clinical and biological effects of neoadjuvant abemaciclib in patients with HPV-negative head and neck squamous cell carcinoma (HNSCC).

  • 12 Mar, 2022
  • 1 location
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes …

tumor cells
  • 16 Oct, 2022
  • 509 locations
Newer Therapeutic Targets in Head and Neck Cancers

survival and proliferation (e.g., TP53, EGFR, MET, and PIK3CA); cell-cycle control (e.g., CDKN2A and CCND1); cellular differentiation (e.g., NOTCH1); and Adhesion and invasion

  • 04 Jun, 2022
  • 1 location